Humana (HUM) Cash & Equivalents (2009 - 2026)

Humana's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $5.0 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 16.49% year-over-year to $5.0 billion; the TTM figure through Mar 2026 stood at $5.0 billion (up 16.49% YoY), while the FY2025 annual figure was $4.2 billion, up 89.1% from the prior year.
• Cash & Equivalents was $5.0 billion for Q1 2026 at Humana, up from $4.2 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $16.2 billion in Q2 2023 to a low of $2.2 billion in Q4 2024.
• Historically, Cash & Equivalents has averaged $7.1 billion across 5 years, with a median of $5.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 215.01% in 2022, then tumbled 66.23% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $5.1 billion in 2022, then slipped by 7.25% to $4.7 billion in 2023, then tumbled by 52.68% to $2.2 billion in 2024, then jumped by 89.1% to $4.2 billion in 2025, then gained by 17.88% to $5.0 billion in 2026.
• The last three Cash & Equivalents figures came in at $5.0 billion (Q1 2026), $4.2 billion (Q4 2025), and $5.4 billion (Q3 2025), per Business Quant data.